CHM.C is breaking out on record volume! The company had 4M in cash at the end of May. The enterprise value of CHM is about 8.5M. Options (.06, .10) and warrants (.50, .70) were issued at significantly higher levels than current stock price. Insiders and consultants hold over 35% of the float. Cannabis sector is starting to wake up a little but it is the Biomedical angle that has me intrigued about CHM. It has acquired a 16.4% stake ImmunoFlex Therapeutics, the company developing products to enhance immunological responsiveness. It is clear that, once released, they will be marketed in the context of COVID-19 pandemic as preventative and immune system strengthening treatments. While the target date for ImmunoFlex products release was vague (“late Fall 2020”), there are signs that it will come sooner rather than later. On September 28th, ImmunoFlex announced hiring of prominent medical professionals and established a Scientific Advisory Board. I suspect we will be seeing more news very soon. On the Cannabis side of things, CHM has recently expanded its Sugarleaf cultivation facility in Washington State by ~ 30%. They are also in the early stages of establishing a California-based operation.